CI Insight is a peer-reviewed journal dedicated to biomedical research, ranging from preclinical to clinical studies.

JCI Insight is a Gold Open Access journal that has a 2022 Impact Factor of 6.3. The Journal publishes well-executed, high-quality studies that provide meaningful contributions to the understanding of the biology and/or treatment of disease, with an emphasis on clinically relevant basic and translational research. Submissions are welcome from all biomedical specialties, including autoimmunity, gastroenterology, immunology, metabolism, nephrology, neuroscience, oncology, pulmonology, vascular biology, and many others.

JCI Insight is self-published by the American Society for Clinical Investigation (ASCI), a nonprofit honor organization of physician-scientists established in 1908. JCI Insight serves to fulfill the ASCI’s objective to advance medical science through the publication of clinically relevant research reports.

Availability and access

• All articles published in JCI Insight are freely available online from the moment of publication. While all articles are open access, those published prior to August 20, 2020, may require permission for use; see License information for details.
• Authors are permitted to post their manuscript on bioRxiv and medRxiv; and may post the manuscript — preferably the final published version — in their institutional or funding agency repository, with a link to the published version for preservation of the scientific record.
• The Journal deposits all content in PubMed Central, which satisfies the NIH Public Access Policy and other similar funding agency requirements.
• JCI Insight meets cOAlition S requirements for authors who receive funding support from Plan S signatories and is fully compliant with Howard Hughes Medical Institute (HHMI), Wellcome, and UK Research and Innovation (UKRI) open access policies.

Submit your work to JCI Insight

• JCI Insight welcomes submissions in the following categories: Research, Resource and Technical Advance, Clinical Medicine, and Physician-Scientist Development. You can use the journal’s submission site by accessing your existing JCI author account or signing up for a new account.
• Start your submission by accessing your author account. If you don’t have an account yet, sign up here.
• If you receive an invitation to transfer your submission from JCI to JCI Insight, the email will include a link to a web page where you can accept or decline the invitation. The invitation to transfer your manuscript to JCI Insight will remain open for 60 days. For more information about the transfer process, click here.
• Click here for information on submission, manuscript and figure preparation, and editorial policies.
• Information on publication costs, copyright information, and article availability is provided here.

Questions about submissions under consideration?

• For any communication with us, please reference the tracking number assigned by the JCI Insight noted in the acknowledgment of your submission. If you do not have this information, reference the manuscript title and corresponding author name. Send email to staff@insight.jci.org or call 734-222-6050.
• To avoid confusion regarding correspondence, inquiries, and decisions, the JCI Insight will typically communicate only with corresponding authors of submissions.

Editors

JCI Insight is headed by Editor in Chief Dr. Kathleen L. Collins, and manuscripts are adjudicated by our team of academic and professional editors. Information about the editors can be found here. In addition, the editors may seek the advice of members of our consulting editorial board.

Key facts

• 2022 Impact Factor: 6.3
• ISSN: 2379-3708
• Indexed in all major resources